PMC:7127386 / 959-1122
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T2 | 104-110 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T4 | 104-110 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T8 | 0-163 | Sentence | denotes | Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T24 | 72-81 | CHEBI:36357;CHEBI:36357 | denotes | compounds |
| T25 | 104-110 | UBERON:0001969 | denotes | plasma |
| T65617 | 72-81 | CHEBI:36357;CHEBI:36357 | denotes | compounds |
| T6727 | 104-110 | UBERON:0001969 | denotes | plasma |
| T83525 | 121-131 | DG_28 | denotes | ions and p |
| T59770 | 133-140 | DG_28 | denotes | vide be |
| T32737 | 145-152 | CHEBI:50266;CHEBI:50266 | denotes | clinica |